Results 221 to 230 of about 218,133 (348)

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Advances in RNA modification in myocardial fibrosis (Review). [PDF]

Int J Mol Med
Wu X, Wang R, Chen X, Wang K.
europepmc   +1 more source

Cardiomyocyte YAP represses myocardial inflammation and fibrosis and restrains MEF2-regulated gene expression

Van K. Ninh, Melissa Barlow, Sidar Aydin, Cameron S. Brand, Justin Yu, Jeffrey M. Smith, Jamie Francisco, Richard Daneman, Kevin R. King, Shigeki Miyamoto, Dominic P. Del Re, Joan Heller Brown   +11 more
openalex   +1 more source

2-APQC, a small-molecule activator of Sirtuin-3 (SIRT3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis [PDF]

Peng Fu, Minru Liao, Wenke Jin, Wei Liu, Zixiang Li, Zhichao Fan, Ling Zou, Siwei Chen, Lingjuan Zhu, Qian Zhao, Gu Zhan, Liang Ouyang, Cheng Peng, Bo Han, Jin Zhang, Leilei Fu   +15 more
openalex   +1 more source

Systemic inhibition of endothelial nitric oxide synthase induces and enhances myocardial fibrosis during cardiac afterload [PDF]

, 2013
Andrey Kazakov, R Hall, P. Mueller-Best, Philippe Jagoda, А. Л. Семенов, Katrin Bachelier, Frank Lammert, Michael Böehm, Ulrich Laufs   +8 more
openalex   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Validation of shear wave elastography for assessing myocardial fibrosis in patients with end-stage heart failure. [PDF]

Eur Heart J Cardiovasc Imaging
Dukefoss HB, Andresen K, Harbo MB, Hasselberg NE, Grødem H, Korsæth T, Romundstad H, Moe KKW, Løvstakken L, Gude E, Dahl TB, Bjørnstad JL, Halvorsen B, Fiane AE, Broch K, Sjaastad I, Edvardsen T, Espe EKS.   +17 more
europepmc   +1 more source

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

ESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén, Bård Andre Bendiksen, Kaja Knudsen Bergo, Emil Knut Stenersen Espe, Gary McGinley, Almira Hasic, Ida Marie Hauge‐Iversen, Hege Katrin Ugland, Xin Shen, Michael Frisk, Nishani S. Mabotuwana, William E. Louch, Rizwan I. Hussain, Lili Zhang, Ivar Sjaastad, Alessandro Cataliotti, Geir Christensen   +16 more
wiley   +1 more source

NETs drive myocardial fibrosis in hypertension via an NF-κB/ferroptosis axis. [PDF]

Front Immunol
Tu Q, Gong X, Yuan X, Tang Y, Huang R, Jiang Q, Li W.   +6 more
europepmc   +1 more source

Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)

ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang, Chunlan Deng, Xiaogang Guo, Hui Yan   +3 more
wiley   +1 more source